ArticleInvestigative ophthalmology & visual science2026
AIF-1 Drives Corneal Neovascularization by Promoting Inflammatory Macrophage Activation via the MAPK and PI3K/AKT/mTOR Signaling Pathways.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to elucidate the precise mechanisms of allograft inflammatory factor 1 (AIF-1)-mediated inflammatory macrophage activation in corneal neovascularization (CNV) pathogenesis and identify a potential therapeutic target. Methods: In vitro, RAW 264.7 macrophages were transfected with small interfering RNA (siRNA) targeting AIF-1. Flow cytometry and immunofluorescence were used to detect macrophage polarization, and ELISA was employed to quantify inflammatory cytokines secreted by macrophages. Intracellular reactive oxygen species (ROS) levels were measured using a ROS detection kit. In vivo, a mouse CNV model was established by alkali burns. AIF-1 siRNA was administered via subconjunctival injection. Inflammatory cytokines and angiogenesis-related factors in the cornea were assessed through Western blot (WB), immunohistochemistry, and immunofluorescence. Slit-lamp imaging and histopathologic analysis were conducted to evaluate angiogenesis and inflammation. Phosphorylation levels of proteins in the MAPK and PI3K/AKT/mTOR pathways were examined by WB. Results: We observed stage-dependent upregulation of AIF-1, paralleled by CNV severity, alongside coordinated overexpression of CD86 and VEGFA. Silencing AIF-1 suppressed inflammatory macrophage activation. AIF-1 promoted macrophage recruitment to the cornea and upregulated TNF-α, IL-1β, IL-6, and VEGFA expression, further exacerbating inflammation, oxidative stress, and angiogenesis in the mouse CNV model. CNV severity was alleviated after AIF-1 inhibition. Notably, AIF-1 drove CNV progression by activating both the MAPK and PI3K/AKT/mTOR signaling pathways. Conclusions: AIF-1 played a pivotal role in CNV progression. AIF-1 promoted inflammatory macrophage activation, exacerbating corneal inflammation and neovascularization via the MAPK and PI3K/AKT/mTOR signaling pathways, which offers novel insights for CNV treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.